INTRODUCTION
Sesquiterpene lactones are isolated from extracts of Mexican-Indian medicinal plants and have been widely used in indigenous medical practices, including treatment of migraines (1,2), inflammation (3) , and tumors (4, 5) . Parthenolide, the major sesquiterpene lactone found in medicinal plants, such as feverfew (Tanacetum parthenium), is known to inhibit IL-1-and TNFα-mediated NF-κB activation which is responsible for its anti-inflammatory activity (6, 7) . Parthenolide has been reported to inhibit NF-κB by targeting the IκB kinase complex (7) . Parthenolide also exerts an antiinflammatory activity by inhibiting the expression of inducible cyclooxygenase, proinflammatory cytokines (8) , and inducible nitric oxide synthase (9) . In contrast, the cytotoxic and antitumor effects of sesquiterpene lactones have not been well studied because of their low potency. Recently it has been reported that parthenolide inhibits the in vitro growth of tumor cells in a cytostatic fashion and it has been proposed that if their selectively cytotoxic or cytostatic actions against tumor cells can be established, sesquiterpene lactones may represent a new class of cancer chemotherapeutic drugs (10) .
Sarcomatoid changes of epithelial neoplasms (carcinomas with spindle -cell components) occur in many organs and histologic types. Sarcomatoid elements in liver cancers are derived from dedifferentiation of hepatocellular carcinoma (HCC) or cholangiocarcinoma. Although the incidences of 8 precipitated with ethanol and sodium acetate, and then 5 µg DNA was separated on a 2% agarose gel.
DNA in the gel was stained with ethidium bromide, visualized under UV light and photographed.
Measurement of Reactive Oxygen Species (ROS) and Mitochondrial Transmembrane
Potential (∆Ψ m ) The intracellular generation of ROS was measured using the oxidation-sensitive fluorescein 5,6-carboxy-2´,7´-dichlorofluorescein diacetate (DCFH-DA) (Molecular Probes, Eugene, OR). For measurement of ∆Ψ m , cells were treated with 10 µM parthenolide for the indicated time.
5,5',6,6' -tetraethylbenzimidazocarbocyanine iodide (JC-1) (Molecular Probes) was added to the medium at 5 µg/ml, and incubation was continued in the dark for 15 min (16) Northern Blot Analysis-Cells were cultured in Dulbecco´s mo dified Eagle medium with 10% fetal bovine serum until they were 60% confluent at which time they were treated with 5 µM parthenolide for 48 hr. Total RNA was extracted from treated or from untreated cells using phenol and 10 hr. The cells were then replenished with complete medium and were treated with equitoxic levels of parthenolide. The cells were lysed in 120 µl lysis buffer at the indicated time intervals and stored at -20ºC until measurement. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega), as instructed by the manufacturer, and was normalized by Renilla luciferase activity.
Glutathione (GSH) Assay-Reduced glutathione was measured using a colorimetric assay kit (OXIS International, Inc., Portland, OR). Cells were treated with either parthenolide alone or in combination with the glutathione precursor N-acetyl-L-cysteine (NAC) for 48 hr or with the glutathione depleting agent L-butathionine-[S,R]-sulfoximine (BSO). Cells treated with BSO were incubated overnight and were then treated with parthenolide after washing for 48 hr. The homogenate was centrifuged at 3000 × g, 4ºC for 10 min, and its supernatant was used for GSH measurement according to the manufacturer's instruction. The cell pellet dissolved in 1M NaOH was used for the measurement of protein content (18) . The GSH content was expressed as nanomoles per miligram protein or percent of the control.
Cell Lysis and Immunoblotting-Cell lysis and immunoblotting was performed as described previously (18) . Cytoplasmic extracts were prepared from cells in lysis buffer (10 mM PIPES, pH 7.4, membranes were removed by centrifugation at 100,000 × g for 45 min at 4°C, as described previously.
The supernatant (S-100 fraction) was used as the cytosolic extract. After adjustment for protein concentration, 30 µg of each cell lysate was boiled in Laemmli buffer and resolved by 15% SDS-PAGE before immunoblot analysis with an antibody against cytochrome c (Pharmingen, San Diego, CA).
Signals were detected using an ECL Western blotting kit (Amersham Pharmacia Biotech, Piscataway, NJ). The mouse anti-poly(ADP-ribose)polymerase (PARP) monoclonal antibody (C2-10), rabbit anticaspase-3 polyclonal antibody, mouse anti-caspase-6 monoclonal antibody (B93-4), mouse anticaspase-7 monoclonal antibody (B94-1), rabbit anti-caspase-8 polyclonal antibody (B9-2), and mouse anti-caspase-9 monoclonal antibody (B40) were purchased from BD PharMingen (San Diego, CA).
The mouse anti-Bcl-2 monoclonal antibody (Ab-1) and mouse anti-Bcl-X L monoclonal antibody (H-5) were obtained from Calbiochem and from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), respectively.
Statistical Anaysis-All data were enered into Microsoft Excel 5.0. GraphPad Software was used to perform paired t tests. All P values of less than 0.05 were considered to be statistically significant.
RESULTS

Inhibition of Cell growth and Induction of Apoptosis by Parthenolide-To determine
whether parthenolide inhibits cell proliferation, SH-J1 cells were cultured on coverslips and exposed to parthenolide at different concentrations (0 µM to 10 µM) for 48 hr. The cells were fixed, stained with the Diff-Quick Stain Set, and cell numbers were histocytologically counted. Parthenolide effectively decreased cell numbers in a dose dependent manner (Fig. 1A) . To examine whether these cytotoxic effects of parthenolide are tumor cell specific, SH-J1 cells and Chang liver cells (which were derived from normal liver tissue) were treated with 10 µM parthenolide for 48 hr. Histocytological examination revealed that the nonmalignant Chang liver cells were resistant to parthenolide-mediated cell growth inhibition, as compared with SH-J1 cells. The cell numbers of Chang liver cells and SH-J1 cells are about 80% and 20% of the untreated controls, respectively (Fig. 1B) . The parthenolide-induced reduction of cell number may result from cell cycle inhibition or cytotoxic cell death. Thus, to measure quantitative cell death, SH-J1 cells, Chang liver cells, and ordinary hepatoma cells (Hep 3B, PLC/PRF/5, and SK-HEP -1) were cultured in 6 cm dishes and exposed to parthenolide at different concentrations (0 µM to 10 µM) for 48 hr. The cells were harvested and dead cells stained with trypan blue dye were counted. Parthenolide decreased SH-J1 cell survival in a dose-dependent manner and the IC 50 for cell survival was about 7.5 µM (Fig. 1C) . The quantitation of cell survival of SH-J1 and Chang liver cells was consistent with the histocytological examination (24.7% ± 2.2% versus 80.0% ± 7.4%, P < 0.01). These results suggest that parthenolide exerts its cytotoxic effects in a tumor cell specific manner. However, cytotoxic cell death was rarely detectable at lower concentrations (1 to 2.5 µM) of parthenolide. Hep 3B and PLC/PRF/5 cells were more susceptible to the drug-induced cell death than were SK-HEP-1 cells. To demonstrate whether parthenolide induces apoptotic cell death, DNA fragmentation was analyzed by gel electrophoresis. SH-J1 cells treated with parthenolide showed increased fragmentation of lower molecular weight DNAs at higher concentrations of parthenolide (between 5 µM and 10 µM) (Fig. 1D ). Lower concentrations of parthenolide (0 µM to 2.5 µM) did not result in any DNA fragmentation. Cells with condensed or fragmented chromosomes and with membrane blebbing, both characteristics indicative of apoptotic morphologies, were examined by staining with Hoechst 33258 following treatment with parthenolide (5 µM to 10 µM) (Fig. 1E) . These results indicate that parthenolide effectively induces apoptosis at the relatively higher concentrations, but not at the lower concentrations.
Parthenolide Inhibits the Cell Cycle (G 2 /M arrest)-Lower concentrations of parthenolide
seem to reduce cell number by cell cycle inhibition. This was supported by the previous report that parthenolide inhibited cell growth in a cytostatic fashion and that the effect was reversible at lower concentrations (10) . Thus, we quantitatively determined the effect of parthenolide on cell proliferation at sublethal concentrations (1 to 3 µM). Using a thymidine uptake assay, DNA synthesis was significantly inhibited by 8% to 51% in cells treated with 1 to 3 µM parthenolide ( Fig. 2A) , which is consistent with a previous report (1) . We next analyzed the impact of parthenolide on the cell cycle of SH-J1 cells. In (Fig. 3A) . NAC was able to completely abrogate parthenolide-induced apoptosis (95 ± 5.5% inhibition, P < 0.01). Vitamin E (200 µM) and vitamin C (200 µM) also effectively inhibited parthenolide-induced apoptosis by 40 ± 3.5 % and by 18 ± 2%, respectively (P < 0.05) (data not shown). Thus, the protection afforded by antioxidants against the induction of cell death by parthenolide suggests that free radicals may be involved in this phenomenon.
To examine this possibility, we measured the levels of intracellular free radicals before and after exposure to parthenolide using the cell permeant dye DCFH-DA. Measurements of cellular fluorescence revealed that parthenolide generated a 3-fold increase of intracellular ROS in SH-J1 cells.
A noncytotoxic dose of NAC completely suppressed parthenolide-induced ROS generation (Fig. 3B) . (Fig. 4B) . Thus, our data suggest that the collapse in ∆Ψ m correlates with mitochondrial cytochrome c release. Because caspase activation plays a central role in the induction of apoptosis (19) , to understand the mechanism of parthenolide-induced apoptosis we examined its effect on the activation of initiator and effector caspases and cleavage of their substrate, PARP. The cleavage and/or the decreased level of the apoptotic substrate PARP and procaspase-7 (which is indicative of apoptotic cell death), were demonstrated along the time course, implying that cytochrome c release leads to apoptotic cell death through oxidative stress as previously described (20) . Interestingly, parthenolide caused a decrease in the procaspase-7 level and its cleavage without changing the level of procaspases-3 or -6, implying that caspase-7 activation is the major effector pathway involved in parthenolide-induced apoptosis. Activation of initiator caspases-8 and -9 were observed in a time dependent manner, as evidenced by decreased level or cleavage of their procaspases.
Endogenous GADD153 Induction by Parthenolide-To identify the gene(s) responsible for
parthenolide-induced apoptosis, we screened genes known to be involved in drug-induced apoptosis through generation of ROS. We focused on GADD153, the growth arrest and DNA damage gene, because parthenolide triggered sudden GADD153 mRNA over-expression during exposure to the drug (Fig. 5A) . To determine the effect of parthenolide on activation of the GADD153 promoter, SH-J1 cells were transiently transfected with pGADD-LUC, which contains the hamster GADD153 promoter coupled to the luciferase reporter gene. The transfected cells were exposed to 5 µM parthenolide for 48 hr ( 
Glutathione-sensitive GADD153 Over-expression during Parthenolide-induced
Apoptosis-Parthenolide-induced apoptosis was completely blocked by NAC, a glutathione precursor, but other general antioxidants, including PDTC, NDGA, vitamin C, and vitamin E, did not block this apoptosis to the same extent, suggesting that the induction of oxidative stress by parthenolide may be related to glutathione-depletion. Thus, we measured the cellular glutathione level during parthenolideinduced apoptosis. Parthenolide exposure resulted in a time dependent decrease in cellular glutathione, which was about 75% of the control level within 48 hr (Fig. 6A) . NAC (800 µM) abrogated the parthenolide-mediated glutathione depletion, but increased the cellular glutathione level (171% ± 15.2%, P < 0.05), implying that parthenolide-induced glutathione depletion activates the glutathione rescue system for compensation, whereas pretreatment with BSO (1 mM) synergistically enhanced parthenolide-mediated glutathione depletion (28.7 ± 1.2%, P < 0.01). BSO-mediated glutathione depletion was recovered by the addition of NAC (137.7 ± 10.2%). Subsequently we examined whether the cellular glutathione level is related to GADD153 mRNA over-expression. Interestingly, the cellular glutathione level was inversely related to GADD153 over-expression (Fig. 6B) , which suggested that parthenolide-mediated glutathione depletion quantitatively triggered GADD153 over-expression.
We further determined whether the glutathione sensitive induction of GADD153 is involved in apoptotic cell execution through activation of initiator and effector caspases. After treatment with 10 µM parthenolide alone, the level of PARP was decreased through cleavage. Furthermore, BSO enhanced the parthenolide-mediated cleavage of PARP, while NAC completely prevented the cleavage of PARP (Fig. 6C) . These findings are consistent with the parthenolide-induced apoptotic cell execution.
Similarly, the decreased level and appearance of cleaved procaspases-9 or -8 was observed. In addition, using flow cytometry we quantified the percentage of the apoptotic cell fraction in sub-G 1 DNA content. Five µM parthenolide caused 42.3% (± 5.5%) apoptotic cell death within 48 hr (Fig. 6D ). NAC completely prevented parthenolide-induced apoptosis (6.5 ± 0.4%), whereas BSO pretreatment synergistically enhanced parthenolide-induced apoptosis (95.5 ± 7.2%, P < 0.01). In addition, NAC overcame the enhancement of parthenolide-induced apoptosis by BSO (4.8 ± 0.6%).
These results are consistent with the glutathione depletion mediated over-expression of GADD153.
Therefore, NAC treatment seems to completely prevent the parthenolide-mediated glutathione depletion and the GADD153 over-expression, which in turn almost blocked apoptotic cell death. Thus, glutathione depletion seems to be in the highest upstream pathway of parthenolide-mediated GADD153 over-expression and apoptotic cell death.
Effect of Modulation of GADD153 Expression on Apoptosis-We next examined whether
GADD153 induction was related to parthenolide-induced apoptosis. We established two stable cell lines that over-expressed GADD153 (J1-G1 and J1-G3). These cells grew slowly without any phenotypic differences, but were readily susceptible to parthenolide-induced apoptosis, compared with vector only transfected controls (J1-C1 and J1-C3) (Fig. 7A) . A two-fold increase of apoptosis was induced by 5 µM parthenolide in the stably GADD153-transfected cells, compared with the vector only transfectants (59.6 ± 5.2% and 55.5 ± 4.0% versus 27.2 ± 3.2% and 29.3 ± 2.1%, P < 0.01). Thus, the induction of GADD153 seems to sensitize the cells to undergo apoptosis. To support this hypothesis, we used transfection of an antisense expression plasmid of GADD153. During parthenolideinduced apoptosis, GADD153 mRNA over-expression was inhibited in SH-J1 cells transfected with the antisense GADD153 cDNA (J1-AS20 and J1-AS29). J1-AS20 and J1-AS29 cells were significantly resistant to 10 µM parthenolide, e.g. about 59.2 ± 7.3% and 65.1 ± 1.8% of GADD153-antisense transfectants survived (P < 0.01), compared with 13.9 ± 2.5% and 16.2 ± 3.0% of vector control cells (pcDNA3-1 and pcDNA3-6) (Fig. 7B) , implying that inhibition of GADD153 mRNA expression correlates well with cell survival in hepatoma cells. These results suggest that GADD153 over-expression following parthenolide treatment may play a role in sensitizing the cancer cells to druginduced apoptotic cell execution.
Over-expression of GADD153 sensitized cells to ER stress through the down-regulation of Bcl-2 expression. This down-regulation of Bcl-2 expression enhanced oxidant injuries, e.g. depletion of cellular glutathione and exaggerated the production of ROS (22). Thus, we determined the effect of parthenolide on Bcl-2 or Bcl-X L expression in hepatoma cells. In the present study, Hep 3B cells are defective in Bcl-2 expression, while SH-J1, SK-HEP-1, and Chang liver cells expressed Bcl-2 protein as we previously observed (18) . Treatment with 10 µM parthenolide for 48 hr did not elicit significant changes of Bcl-2 or Bcl-X L expression levels in hepatoma cells (Fig. 7C) . Time course analysis also revealed that Bcl-2 protein expression did not change or was only slightly increased in the early period of parthenolide treatment in SH-J1 cells (right).
Parthenolide-mediated tumor cell-specific oxidative stress-To determine whether the increase in oxidative stress is caused by increased production of ROS or by increased consumption of GSH during detoxification of parthenolide, we treated SH-J1 cells with either a nontoxic dose of BSO (Fig. 8A) . These results imply that GSH depletion, rather than ROS generation, plays a major contributing role in parthenolide-mediated oxidative stress. Next, we needed to explain the difference in the sensitivity to parthenolide between tumor cells and nontumor cells. We measured cellular GSH content before and after 48 h of parthenolide treatment (10 µM). The GSH content of both types of cells were similar (~20 nmol/mg protein) before the treatment, which is consistent with a previous report of hepatoma cells (23).
However, parthenolide-treatment significantly decreased the cellular GSH content in SH-J1 cells, whereas it increased the cellular GSH content in Chang liver cells (Fig. 8B) . These findings suggest that the tumor cells are more sensitive to parthenolide, i.e. they experience a greater decrease in cellular GSH content in response to parthenolide. To support this hypothesis, we checked the expression of γ-glutamyl-cysteine synthetase (γ-GCS), which is the rate-limiting enzyme in the synthesis of GSH (24), and of the multifunctional detoxification enzyme glutathione S-transferase π (GST-π), which plays a role in determining sensitivity to some drugs (25). Constitutive expression levels of γ-GCS mRNA were slightly different in the two cell lines although the cellular GSH levels were similar. Intriguingly, the basal expression of GST-π mRNA was much less (25%) in the tumor cells than in the nontumor cells.
Parthenolide induced the over-expression of GST-π mRNA in SH-J1 cells, but it was still much less (50%) than that found in Chang liver cells.
DISCUSSION
Regarding the potential use of parthenolide and related compound s as chemotherapeutic agents, evidence is required that the agent(s) has a pronounced differential effect on tumor cells of any type compared with normal cells. Interestingly, parthenolide showed tumor cell-specific effects with respect to cytotoxic cell injuries. Cytotoxic events may be irreversible and can result from immediate effects (such as major disruption of cell membranes) or from delayed effects (such as triggering of apoptosis or interference with cell division). Our study revealed that parthenolide effectively induces apoptosis in hepatoma cells. As parthenolide was reported to inhibit cell growth in a cytostatic fashion, this study also showed that a sublethal dose of parthenolide induces G 2 /M arrest in cancer cells as other apoptosis-inducing anticancer drugs frequently induce G 2 /M arrest (26). In contrast, human sarcomatous cholangiocarcinoma cells (SCK) treated with parthenolide showed G 1 arrest (data not shown). Thus, inhibition of the cell cycle phase seems to be cell-specific although the exact molecular mechanism remains unknown.
NF-κB is a heterodimeric transcription factor which is usually sequestered in the cytoplasm by IκB proteins (27). In most cell types, NF-κB induces the expression of proinflammatory and antiapoptogenic genes and protects them against TNF, chemotherapeutic agents and/or radiation (27-29).
Recently, NF-êB was reported to repress GADD153 activation and parthenolide was shown to GADD153 is a gene that is strongly transcriptionally activated by various types of stress and by chemotherapeutic drugs. Induction of the GADD153 gene by anti-cancer agents has been shown to be associated with cell injury/apoptosis (21, 41, 42) and to be attenuated in drug-resistant cells (43) .
Furthermore, introduction of GADD153 into cancer cells increased their sensitivity to anticancer agents (44) . Thus, GADD153 seems to be an important target gene for apoptotic cell death induced by anticancer agents. GADD153 is known to be an AP-1-regulated gene that plays a critical role in the AP-1-associated signal transduction pathway(s) leading to apoptosis following oxidative stress (45) .
GADD153 over-expression was detected by Northern blot in a time dependent manner. It seems unclear whether parthenolide has a direct effect on GADD153, or whether changes in GADD153 expression occur farther down-stream of the immediate effects of parthenolide. GADD153 was reported to be a down-stream gene of the immediate early response gene NF-κB. NF-κB represses GADD153 promoter activity (30). Parthenolide-induced apoptotic cell death was completely blocked by NAC, but other general antioxidants including PDTC and NDGA did not seem to have much effect on this apoptosis, suggesting that parthenolide-mediated oxidative stress may be related to glutathionedepletion. This hypothesis is supported by a recent report that parthenolide contains an α,β-unsaturated lactone that is capable of participating in a Michael addition with compounds containing an -SH group.
Thus, it could conjugate with the antioxidant glutathione, levels of which are reduced in treated organisms (46) . Accordingly, our study demonstrates that parthenolide decreases the cellular glutathione level and that parthenolide-mediated glutathione depletion is modulated by BSO or NAC. Furthermore, the modulation of oxidative stress changed GADD153 induction, i.e. a decreased glutathione level inversely correlates with GADD153 mRNA level, caspase activation, and subsequent apoptotic cell death. Thus, glutathione depletion may be in the upstream pathway of the oxidative stress-mediated apoptosis following parthenolide treatment. These results are supported by a previous report (47) wherein NAC completely abrogated the GADD153 over-expression-induced by cadmium chloride, an oxidative stress inducing agent, by interacting with and decreasing the levels of cellular glutathione. The cleavage of PARP was indicative of apoptotic cell death in parthenolide-treated cells and this cleavage was enhanced by BSO and was completely abrogated by NAC, implying that glutathione depletion is critical in triggering apoptotic cell execution. Activation of the initiator caspases-8, and -9 was similarly enhanced or inhibited by BSO or NAC, respectively.
In this study, ectopic GADD153 over-expression sensitized cells readily underwent apoptosis, whereas inhibition of GADD153 over-expression correlated with drug resistance. Previously, parthenolide has been found to inhibit protein tyrosine kinases (48) and protein kinase C (49). Protein kinase inhibitors have also been shown to cause apoptosis although their exact mechanism is still unclear (50), and such inhibitors represent a promising new class of therapeutic agents against cancer. However, pretreatment of SH-J1 cells with a nonspecific inhibitor of protein kinase C (H7), or with a tyrosine kinase inhibitor (genestein) had no effect on the basal expression of GADD153 mRNA and had a slight modulation of parthenolide-induced GADD153 mRNA levels (data not shown), which implies that the parthenolide-induced expression of GADD153 is independent of protein kinase c or tyrosine kinase.
These findings are consistent with the effects of protein kinase inhibitor and genestein on methyl methanesulfonate-induced GADD153 mRNA expression in HeLa cells (47) . In addition, the GADD153-transfected cells had an increased sensitivity to parthenolide-mediated cytotoxicity that was associated with cell death. Other groups have previously reported that induction of GADD153 correlates with the onset of apoptosis (51, 52). In contrast, it has been recently reported that GADD153-mediated down-regulation of Bcl-2 expression enhanced oxidant injuries, e.g. depletion of cellular glutathione and exaggerated production of ROS (22 Sesquiterpene lactones possessing an á-methylene ã-lactone functionality are electrophilic agents and are thus apt to react with biological nucleophiles, such as the sulphydryl group of GSH, proteins, and parts of DNA (53). Previously, reduction of cellular GSH levels in vitro and in vivo has been reported for tumor cells exposed to sequiterpene lactones (54, 55). Parthenolide, furthermore, also possesses an epoxide moiety, which is a second site for potential nucleophilic attack by an amino acid side chain. Accordingly, the present study showed that the parthenolide-mediated oxidative stress mainly resulted from the GSH depletion and that the tumor cell sensitivity to this sesquiterpene lactone seemed to correlate with glutathione metabolism. The critical reaction for GSH synthesis is catalyzed by γ-GCS and by glutathione synthetase (56, 24). The cellular level of GSH is also controlled by glutathione peroxidase and by GST (24). Particularly, GST-π, a major cytoplasmic isoform of GSTs, is the most prevalent isoform expressed in tumor cells and in neoplastic tissues (57) and frequently plays a role in determining the sensitivity to some drugs (58). The expression level of γ-GCS did not seem to be proportional to the cellular GST content between these two cell lines, even in drug-treated cells.
However, untreated tumor cells expressed markedly less GST-π mRNA than did nontumor cells. GST-ð forms a drug-GSH adduct, which is in turn transported outside the tumor cells (59) and this efflux activity is elevated in cells resistant to the drug. Thus, the abundant expression of GST-π may result in the acquisition of drug resistance in Chang liver cells. Furthermore, parthenolide induced the overexpression of GST-π mRNA only in tumor cells, which seems to be relevant to the parthenolidemediated decrease of cellular GSH concentration. Considering that the tumor cell sensitivity to parthenolide is potentiated by lowering GSH levels by treatment with BSO, GSH homeostasis maintained by an interaction between GST-π and γ-GCS may be critical for parthenolide-induced apoptotic cell execution in the parthenolide-sensitive hepatoma cells.
In summary, it is not currently known how over-expression of the GADD153 gene connects to the downstream signal transduction pathway that leads to apoptosis and cell growth arrest. However, our data reveal that parthenolide triggers apoptotic cell death through oxidative stress during which GADD153 is over-expressed and sensitizes the tumor cells to apoptosis. Apoptotic cell death and cell growth inhibition appear to contribute to the anticancer effects of parthenolide and these anticancer effects may be further modulated by pro-or anti-oxidants in a glutathione sensitive manner. Immunodetection of PARP, caspases-7, -8, and -9 was performed by specific antibodies as detailed in the Methods and was visualized by enhanced chemiluminescence. parthenolide for 48 hr and were then cultured in parthenolide-free medium to which actinomycin D (ActD, 5 µg/ml) or vehicle with or without 5 µM parthenolide (P) was added. Total RNA was extracted from the three sets at subsequent time points (left). Autoradiograms were read using densitometric scanning and were normalized against GAPDH mRNA levels (right). 
